XORTX Therapeutics Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc. reported Q3 2025 financial results, showing a decrease in total assets from $4.09M to $2.81M and an increase in liabilities. The financials reflect ongoing R&D and investor relations costs. Analysts have mixed views, with a Buy rating and C$14.00 price target, but AI analysis suggests an Underperform rating due to no revenue and consistent losses. Potential FDA advancements for gout treatment offer some hope. The company focuses on therapies for kidney disease, diabetes, and cardiovascular disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments